文献速递妇科

晚期卵巢癌谁真正从腹腔内化疗获益?AICE试验的无治疗生存分析

Who really benefits from intraperitoneal chemotherapy for advanced ovarian cancer? A treatment-free survival analysis of the AICE trial.
PubMed 文献 · BJOG · 2022-01-01

基于AICE试验(NCT01669226)延长随访至2020年8月27日,按肿瘤负荷分为高负荷组和低负荷组,分析腹腔/静脉(IP/IV)化疗与静脉化疗的无治疗生存。高负荷组IP/IV组限制平均无治疗生存33.9个月 vs 静脉组18.7个月(p=0.005),质量调整总生存获益13.2-16.0个月;低负荷组无生存获益(无治疗生存p=0.268)。

要点

  • 高负荷组IP/IV化疗较静脉化疗延长无治疗生存(33.9 vs 18.7个月,p=0.005)。
  • 高负荷组IP/IV化疗质量调整总生存获益13.2-16.0个月。
  • 低负荷组IP/IV化疗无治疗生存无显著获益(p=0.268)。

核心结论

  • 高负荷亚组中IP/IV化疗在所有效用权重值下无治疗生存和质量调整总生存均长于标准静脉化疗,而低负荷亚组患者未从该治疗获益。
  • 卵巢癌肿瘤负荷应在决定IP/IV还是静脉治疗前进行评估。

研究设计与样本

  • AICE试验(NCT01669226)的延长随访,数据截止2020年8月27日,五中心试验。
  • 患者按肿瘤负荷分为高肿瘤负荷(HTB)和低肿瘤负荷(LTB)亚组。
  • 总生存分为方案治疗暴露时间(T)、无后续治疗或死亡时间(TFS)和首次后续治疗后时间(REL),计算质量调整总生存。

主要发现

  • HTB亚组中IP/IV组与IV组的限制平均TFS分别为33.9个月和18.7个月(p=0.005)。
  • HTB亚组质量调整总生存获益为13.2-16.0个月。
  • LTB亚组中IP/IV治疗在TFS(p=0.268)或质量调整总生存(范围1.4-6.3个月)方面均无生存获益。

关键数值与推荐

  • 采用96个月限制平均时间估算每条Kaplan-Meier曲线下面积,并用阈值效用分析展示质量调整总生存比较。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate whether peritoneal disease extent can predict the survival benefit of intraperitoneal/intravenous (IP/IV) chemotherapy in ovarian cancer. DESIGN: A treatment-free survival (TFS) analysis. SETTING: Five-centre trial. POPULATION: An extended follow-up of the Additional Intraperitoneal Cisplatin and Etoposide in ovarian cancer (AICE) trial (NCT01669226), with data cut-off on 27 August 2020. Patients were categorised into subgroups with high tumour burden (HTB) and low tumour burden (LTB). METHODS: Overall survival (OS) was divided into time on protocol treatment exposure (T), time free of subsequent treatment or death (TFS) and time after the first subsequent therapy (REL). TFS analyses and quality-adjusted OS were calculated by multiplying the mean time in each health state by its assigned utility: quality-adjusted OS = ut × T + TFS + urel × REL. MAIN OUTCOME MEASURES: The area under each Kaplan-Meier curve was estimated using the 96-month restricted mean time, with threshold utility analyses used to illustrate quality-adjusted OS comparisons. RESULTS: In the HTB subgroup, the restricted mean TFS was 33.9 months and 18.7 months in the IP/IV and IV groups, respectively (p = 0.005), with a significant quality-adjusted OS gain (13.2-16.0 months). In the LTB subgroup, IP/IV therapy yielded no survival benefit in either TFS (p = 0.268) or quality-adjusted OS (range: 1.4-6.3 months). CONCLUSIONS: Both TFS and quality-adjusted OS was longer across all utility weight values with IP/IV than with standard IV therapy in the HTB subgroup, whereas patients in the LTB subgroup did not benefit from the therapy. The tumour burden of ovarian cancer should be assessed before deciding on IP/IV versus IV treatment.

来源:BJOG,查看原文。版权归原作者所有。

引用

  1. Xiang L, Shen L, Chen Y, et al. Who really benefits from intraperitoneal chemotherapy for advanced ovarian cancer? A treatment-free survival analysis of the AICE trial. BJOG. 2022. PMID: 36485070. doi:10.1111/1471-0528.17326

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。